Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Receivables (2016 - 2026)

Mimedx's Receivables history spans 17 years, with the latest figure at $46.0 million for Q1 2026.

  • On a quarterly basis, Receivables fell 26.09% to $46.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $46.0 million, a 26.09% decrease, with the full-year FY2025 number at $84.4 million, up 43.16% from a year prior.
  • Receivables hit $46.0 million in Q1 2026 for Mimedx, down from $84.4 million in the prior quarter.
  • Over the last five years, Receivables for MDXG hit a ceiling of $84.4 million in Q4 2025 and a floor of $37.7 million in Q2 2022.
  • Historically, Receivables has averaged $54.0 million across 5 years, with a median of $52.8 million in 2024.
  • Biggest five-year swings in Receivables: surged 44.71% in 2025 and later decreased 26.09% in 2026.
  • Tracing MDXG's Receivables over 5 years: stood at $43.1 million in 2022, then rose by 25.04% to $53.9 million in 2023, then increased by 9.45% to $59.0 million in 2024, then soared by 43.16% to $84.4 million in 2025, then tumbled by 45.46% to $46.0 million in 2026.
  • Business Quant data shows Receivables for MDXG at $46.0 million in Q1 2026, $84.4 million in Q4 2025, and $78.2 million in Q3 2025.